TScan Therapeutics Announces Two-Year Relapse Data for TSC-101 Cell Therapy Ahead of Pivotal Trial Launch
Key Insights
TScan Therapeutics will present two-year relapse data from its ALLOHA Phase 1 trial showing 82% of patients treated with TSC-101 remained relapse-free compared to 64% in the control arm.
The company has reached agreement with FDA on a registrational path forward for TSC-101 as a treatment for acute myeloid leukemia (search) and myelodysplastic syndromes (search).
A pivotal trial for TSC-101 is scheduled to launch in the second quarter of 2026, utilizing an improved commercial-ready manufacturing process.
TScan Therapeutics will present promising two-year relapse data from its ALLOHA Phase 1 trial at the upcoming American Society of Hematology Annual Meeting, showing that 82% of patients treated with TSC-101 remained relapse-free compared to 64% in the control arm. The clinical-stage biotechnology company announced it will host a virtual key opinion leader event on December 8 to discuss these updated results and the future market opportunity for its hematologic malignancy program.
Strong Efficacy Signal in Hematologic Malignancies
The ALLOHA Phase 1 trial is evaluating TSC-101, an allogeneic, donor-derived T-cell therapy that targets minor histocompatibility antigens (search) to eliminate residual disease after hematopoietic cell transplantation. The therapy demonstrated a meaningful relapse-free benefit, with 14 out of 17 patients in the treatment arm remaining relapse-free compared to 9 out of 14 patients in the control arm.
TSC-101 showed a favorable safety profile and durable long-term persistence, with TCR-T cells detected more than two years post-infusion. The data revealed a clear relationship between dose and persistence, supporting the therapeutic approach's viability for preventing relapse in patients with hematologic malignancies (search) undergoing allogeneic hematopoietic cell transplantation.
Regulatory Pathway Established
Following a productive End-of-Phase 1 meeting with the FDA, TScan Therapeutics has agreed on the registrational path forward for the TSC-101 program as a treatment for acute myeloid leukemia (search) and myelodysplastic syndromes (search). This regulatory milestone positions the company to advance toward a pivotal trial scheduled to launch in the second quarter of 2026.
The company has implemented an improved commercial-ready manufacturing process in the ongoing ALLOHA Phase 1 trial, which will be utilized in the upcoming pivotal study. This manufacturing advancement represents a critical step toward potential commercialization of the TCR-T therapy.
Expert Panel Discussion
The virtual event will feature key opinion leaders including Dr. Ran Reshef, Director of Translational Research at Columbia University Irving Medical Center's Blood and Marrow Transplantation Program, alongside TScan executives CEO Gavin MacBeath and Senior Vice President of Market Access Stephen Camiolo. The panel will provide an in-depth review of the ASH poster presentation and discuss the unmet medical need and potential market opportunity for TSC-101 and follow-on product candidates.
TScan Therapeutics focuses on developing T cell receptor-engineered T cell therapies for cancer treatment, with TSC-101 representing its lead candidate for hematologic malignancies (search). The company is also developing multiple TCR-T therapy candidates for solid tumors and applying its TargetScan platform to discover novel targets in T cell-mediated autoimmune disorders.